Drug Database: Doravirine / Islatravir

What is Idvynso?What is Idvynso?

What is Idvynso?

Idvynso is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV in adults who meet certain requirements, as determined by a health care provider.

Idvynso is a complete HIV treatment regimen and should not be used with other HIV medicines.

Idvynso contains two different medicines: doravirine and islatravir.

For more information on the use of Idvynso in people with HIV, please refer to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. (The Adult and Adolescent ARV Guidelines may not yet be updated at the time this drug record is published. Please refer to the Guidelines for new updates.)

HIV medicines cannot cure HIV, but using HIV medicines as directed by a health care provider helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission. If you are using HIV medicines, do not cut down on, skip, or stop using them unless your health care provider tells you to.

What should I tell my health care provider before taking Idvynso?What should I tell my health care provider before taking Idvynso?

What should I tell my health care provider before taking Idvynso?

Before taking Idvynso, tell your health care provider:

• If you are allergic to any of the HIV medicines in Idvynso (doravirine or islatravir) or any other medicines.
• If you have ever had liver problems, including hepatitis B virus infection (HBV).
• If you have kidney problems.
• If you have any other medical conditions.
• If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking Idvynso during pregnancy. For more information on the use of Idvynso during pregnancy, please refer to the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. (The Perinatal Guidelines may not yet be updated at the time this drug record is published. Please refer to the Guidelines for new updates.)
• If you are breastfeeding or plan to breastfeed. For mothers with HIV in the United States, the Guideline recommends speaking with your health care provider to discuss options for feeding your baby. Mothers with suppressed viral load have a less than 1% chance of transmitting HIV to their baby via their own milk. Although most medicines are safe to use while breastfeeding, some medicines should be avoided. Always let your health care provider know about all the medicines and supplements you are using before you start breastfeeding.
• If you are using hormone-based birth control (such as injections, vaginal rings, implants, contraceptive patches, or birth control pills). Idvynso may make these forms of birth control less effective. Your health care provider can help you decide how to adjust your birth control while you are taking Idvynso. For more information about using birth control and HIV medicines at the same time, view the HIVinfo HIV and Birth Control infographic.
• About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Idvynso may affect the way other medicines or products work, and other medicines or products may affect how Idvynso works. Taking Idvynso together with certain medicines or products may cause serious side effects. For a list of medicines that may interact with Idvynso, see the drug label or ask your health care provider or pharmacist. You can also look up potential interactions between your HIV medicines and other drugs using the HIV Drug Interaction Checker online.

How should I take Idvynso?How should I take Idvynso?

How should I take Idvynso?

Idvynso comes in tablet form. Each tablet contains:

• 100 mg doravirine
• 0.25 mg islatravir

Take Idvynso according to your health care provider’s instructions. Do not miss a dose of Idvynso, and do not change your dose or stop taking Idvynso without first talking with your health care provider.

Take Idvynso by mouth with or without food. Do not take Idvynso with other HIV medicines.

If you also take the medicine rifabutin during treatment with Idvynso, you may not have enough doravirine in your blood. (Doravirine is one of the medicines in Idvynso.) Your health care provider will prescribe an additional dose of doravirine for you to take. Follow your health care provider’s instructions about when to take doravirine and how much to take. This is usually one tablet of doravirine about 12 hours after your last dose of Idvynso.

If you have taken too much Idvynso, contact your health care provider or local poison control center (1-800-222-1222 or online) right away, or go to the nearest hospital emergency room.

For more information on how to take Idvynso, see the FDA drug label.

• For more information on the use of Idvynso in people with HIV, please refer to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. (The Adult and Adolescent ARV Guidelines may not yet be updated at the time this drug record is published. Please refer to the Guidelines for new updates.)
• This Patient Version drug summary is based on the following FDA label(s): Tablet (film coated). The Patient Package Insert includes information for people taking Idvynso.
• Idvynso-related research studies, from ClinicalTrials.gov. (The ClinicalTrials.gov search can be modified so that you can get results that better match your interests.)
• A list of FDA-approved HIV medicines, from HIVinfo.

Manufacturer Information

Merck & Co., Inc.
Main number: 908-740-4000
Patient assistance: 800-727-5400

Last Reviewed: April 23, 2026

home message